Malik 1980.

Methods	Allocation: randomly allocated. Blindness: double (identical capsules). Design: 2 parallel groups, single centre. Duration: 28 days. Analysis: intention‐to‐treat not performed in the trial. Country: India.
Participants	Diagnosis: schizophrenia, no further details. N=54. Age: range 14‐19 years mean ˜17 years. Sex: M 25, F 27 (2 not reported). Setting: hospital. History: adolescent schizophrenics. Exclusion: sensivity to study drugs, ECT in the last 8 weeks, brain syndrome, convulsive disorders, mental retardation or autism.
Interventions	1. Trifluoperazine: dose mean 23.57 mg/day, maximum 35 mg. N=27. 2. Loxapine succinate: dose mean 91.5 mg/day, maximum 120 mg. N=27. Antiparkinson medication as required.
Outcomes	Global state: (CGI, patient's self evaluation). Patient's drug preference. Leaving the study early. Unable to use ‐ Mental state: (BPRS ‐ no SD). Use of antiparkinson drugs ‐ no data. Physiological measures: (BP, pulse ‐ no data). Laboratory tests ‐ no data.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear